Advertisement
Advertisement
TOPIC
 / company

Insilico Medicine

(英矽智能)

Related Topics:
Insilico Medicine
英矽智能
Insilico, based in Boston and Hong Kong, uses end-to-end generative artificial intelligence (AI) to identify novel targets and disease hypotheses and generative innovative drug candidates. Its Pharma.AI platform operates across biology, chemistry and clinical medicine to identify drug candidates.
Illustration: Lau Ka-kuen
China’s private sector

With AI able to predict disease, can we treat ageing like a ‘bug’ in the system?

AI is transforming longevity as companies like METiS TechBio and Human Longevity use algorithms to combat ageing and predict health risks.

China’s private sector

Insilico, US partner to build AI models predicting disease decades ahead

China’s private sector

China’s drug makers are speeding up – will AI be their secret weapon?

Banking & finance

Insilico Medicine signs AI drug development deal with Eli Lilly

Reaching development, regulatory and commercial milestones could see value of deal hit around US$2.75 billion.

Life Star2, Insilico’s automation lab. Photo: Handout
Wealth management

Hong Kong family office summit draws Pop Mart billionaire among global guests

City is ‘strong and unwavering’ as wealth management hub, Chief Executive John Lee says to kick off fourth Wealth for Good summit.

Banking & finance

China investors energise Hong Kong biotech stocks. Is foreign money missing out?

Stock Connect reshuffle reflects biotech sector’s growing role on international stage, though overseas funds remain cautious.

Advertisement
Advertisement
Advertisement
Biomedicine: Companies

Insilico Medicine advances Middle East push with UAE AI drug discovery deal

Hong Kong-listed biotech firm’s shares jump after announcing partnership to use AI tools in drug discovery in the United Arab Emirates.

The agreement was reached during the World Health Expo in Dubai between February 9 and 12, about two weeks before the United States and Israel launched military strikes on Iran. Photo: Shutterstock
Two Sessions 2026

China and Hong Kong should relax biotech listing rules, venture capitalist says

Foreign investors are returning to China’s healthcare sector, but IPO bottlenecks and takeover rules could deter deals, VC Nisa Leung says.

Biomedicine: Companies

Insilico signs US$888 million AI drug deal days after Hong Kong IPO

Multi-year partnership with France’s Servier will use Insilico’s AI platform to explore novel cancer drugs.

Banking & finance

The ‘biology winter’ thaws: why investors are buying Hong Kong’s biotech IPOs

A wave of China out-licensing deals is feeding a biotech comeback in Hong Kong, where IPOs and follow-on placements are surging.

Healthcare firms now account for about a fifth of the more than 300 listing applications in the city. Photo: Shutterstock
Hong Kong economy

Editorial | Hong Kong’s IPO market rings in 2026 on a high note

The city catapulted itself into the global top spot for initial public offerings in 2025, with another strong pipeline of listings expected this year.

Bonnie Chan Yiting (centre), CEO of Hong Kong Exchanges and Clearing, with (left to right) Li Yi, chairman of Beijing 51WORLD Digital Twin Technology; Alex Zhavoronkov, chairman and CEO of Insilico Medicine; Li Zhichen, chairman and CEO of OneRobotics (Shenzhen); Sun Laichun, chairman of Shanghai Forest Cabin Cosmetics Group; Geng Dawei, executive director and general manager of Shenzhen Xunce Technology; and Brian B.Y.Chen, chairman of USAS Building System (Shanghai). The six companies began trading on the Hong Kong exchange on December 30. Photo: Sun Yeung
Hong Kong stock market

Hong Kong stocks edge higher on last full trading day of year

Hang Seng Index edges higher as Chinese yuan surpasses 7 against US dollar for first time since May 2023.

IPO

China vital to Insilico’s plan to build biotech’s AI ‘Einstein’ for new drugs

US firm, backed by Fosun and Tencent, expands research base in China as it develops an AI-powered drug-discovery tool.

IPO

Insilico Medicine leads 6 Hong Kong IPOs, capping banner fundraising year

Debutants raise total of US$899 million as exchange wraps up one of the most active months for IPOs since 2021.

Executives of the six companies celebrate their listings in a gong ceremony at Hong Kong Exchanges and Clearing in Central on December 30, 2025. Photo: Sun Yeung
IPO

Holiday rush: Hong Kong IPO market sparkles with busiest December in years

From biotech to AI, December’s listings – including at least 15 down the stretch – crown the city’s revival in equity fundraising.

Insilico Medicine says its listing could raise up to HK$2.3 billion. Photo: Shutterstock
Biomedicine: Companies

China’s drug innovators bank on AI to hasten discovery to commercial success

A deal between Shenzhen-based XTalPi and US firm DoveTree shows Chinese biotech AI capabilities are gaining recognition.

videocam
Artificial intelligence

Biotech firm touts new AI drug discovery amid third Hong Kong IPO attempt

Insilico Medicine said results of a clinical trial in China showed positive results in treating idiopathic pulmonary fibrosis.

Advertisement
Advertisement
Advertisement
IPO

More Hong Kong IPO hopefuls emerge as sentiment draws investors

SAIC Mobility unveiled its plans on Friday; others like Mirxes, Insilico and CiDi revive their applications, according to exchange filings.

videocam
Exchange Square in Central. Photo: Jelly Tse
Hong Kong’s belt and road impact

How two Hong Kong firms’ innovative solutions enhance well-being in belt and road regions

Modern Dental Group and Insilico Medicine keen to use city’s unrivalled global connections to create a healthier world.

In partnership with:
Belt and Road Office
Artificial intelligence

Generative AI helps Hong Kong’s Insilico Medicine design potential new IBD drug

Using AI, Insilico took only 12 months from initiating the project to nominating the molecule for preclinical trials, instead of several years.

Science

Drug development can take over a decade. AI helped make a medicine in 18 months

Evidence that AI tools can slash years off early-stage analysis will ‘revolutionise drug discovery’, researchers say.

videocam
Insilico Medicine has harnessed AI-drug discovery to map out an experimental drug for a lung disease that affects millions of people around the world. Photo: Insilico Medicine
Banking & finance

Hong Kong’s Insilico sells cancer drug candidate in potential US$500 million deal

Stemline Therapeutics, a wholly-owned unit of Menarini Group, will make a US$12 million upfront payment to Insilico under the agreement, which will be followed by sales royalties worth up to ‘double digits’.

Hong Kong-based AI-driven company sells potential breast cancer drug in deal whose value could exceed US$500 million
Medicine

Exclusive | Hong Kong’s Insilico, Aramco to partner on sustainable fuels and materials

AI drug discovery unicorn Insilico Medicine is set to sign a deal with Saudi Arabia’s Aramco and a subsidiary during Hong Kong leader John Lee Ka-chiu’s official visit to the country.

videocam
Medicine

Sanofi signs with Hong Kong biotech firm Insilico to spur AI drug discovery

French pharmaceutical giant Sanofi will collaborate with Hong Kong-based biotech firm Insilico Medicine in a deal worth up to US$1.2 billion to speed up the drug-discovery process using artificial intelligence.

videocam
Wellness

How AI is revolutionising drug industry by cutting research time

AI can save up to two years in pharmaceutical research and development time, says CEO of drug-development company Insilico Medicine, which is moving its headquarters to Hong Kong.

How AI is revolutionising drug industry by cutting pharmaceutical development time, says leading company
Help preserve 120 years of quality journalism.
SUPPORT NOW
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement